Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases

被引:0
作者
Zeng, Cong [1 ,2 ,3 ,4 ]
Chen, Yan [1 ,2 ,3 ,4 ]
Hua, Juan [1 ,2 ,3 ,4 ]
Liu, Yi [1 ,2 ,3 ,4 ]
Cheng, Ting-ting [1 ,2 ,3 ,4 ]
Ma, Xia [1 ,2 ,3 ,4 ]
Chen, Xu [1 ,2 ,3 ,4 ]
Wang, Shi-yu [1 ,2 ,3 ,4 ]
Xu, Ya-jing [1 ,2 ,3 ,4 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China
[2] Xiangya Hosp, Natl Clin Res Ctr Geriatr Dis, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Hunan Hematol Neoplasms Clin Med Res Ctr, Changsha, Peoples R China
[4] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Changsha, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
peripheral blood; cord blood; haploidentical donor; allogeneic hematopoietic stem cell transplantation; hematologic malignancy; VERSUS-HOST-DISEASE; REGULATORY T-CELLS; BONE-MARROW; GVHD;
D O I
10.3389/fimmu.2022.980464
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB) from March 2017 to June 2020 were analyzed in this retrospective study. Anti-thymocyte globulin(ATG) was administered at a dose of 7.5 mg/kg. The median time for neutrophil and platelet engraftment was 13(range: 8-22) days and 14(range: 8-103) days, respectively. The 30-day cumulative incidence of neutrophil engraftment was 100%, and the 100-day cumulative incidence of platelet engraftment was 95%. All patients achieved complete haploidentical peripheral blood stem cell engraftment, and no cord blood chimerism was observed. The cumulative incidence of grades II-IV and grades III-IV acute graft-versus-host disease (aGVHD) on 100-day was 26.3%(95%CI: 17.2%-36.3%) and 5.0%(95%CI: 1.6%-11.4%), respectively. The estimated cumulative incidence of chronic GVHD (cGVHD) and moderate-severe cGVHD at 3-year was 43.3%(95%CI: 31.6%-54.4%) and 16.0%(95%CI: 8.7%-25.2%), respectively. The estimated 3-year cumulative incidence of relapse and non-relapse mortality was 18.8%(95%CI: 10.0%-29.7%) and 17.8%(95%CI: 9.9%-27.5%), respectively. The estimated 3-year probabilities of overall survival, disease-free survival, GVHD/relapse-free survival were 77.6%(95%CI: 68.3%-88.1%), 63.4%(95%CI: 52.6%-76.5%), and 55.5%(95%CI: 44.8%-68.7%), respectively. These satisfying results suggested that haplo-PBSCT combined with UCB is an alternative transplantation protocol for hematologic malignancies.
引用
收藏
页数:9
相关论文
共 24 条
  • [1] Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts
    Arcuri, Leonardo Javier
    Hamerschlak, Nelson
    Rocha, Vanderson
    Bonfim, Carmem
    Kerbauy, Mariana Nassif
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (09): : 782.e1 - 782.e7
  • [2] Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review
    Fisher, Sheila A.
    Lamikanra, Abigail
    Doree, Carolyn
    Gration, Betty
    Tsang, Pat
    Danby, Robert D.
    Roberts, David J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) : 448 - 463
  • [3] Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice
    Ganguly, Sudipto
    Ross, Duncan B.
    Panoskaltsis-Mortari, Angela
    Kanakry, Christopher G.
    Blazar, Bruce R.
    Levy, Robert B.
    Luznik, Leo
    [J]. BLOOD, 2014, 124 (13) : 2131 - 2141
  • [4] Human umbilical cord blood-derived stromal cells prevent graft-versus-host disease in mice following haplo-identical stem cell transplantation
    Hao, Lei
    Gao, Lei
    Chen, Xing-Hua
    Zou, Zhong-Min
    Zhang, Xi
    Kong, Pei-Yan
    Zhang, Cheng
    Peng, Xian-Gui
    Sun, Ai-Hua
    Wang, Qing-Yu
    [J]. CYTOTHERAPY, 2011, 13 (01) : 83 - 91
  • [5] Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation
    Harada, Kaito
    Fuji, Shigeo
    Seo, Sachiko
    Kanda, Junya
    Ueki, Toshimitsu
    Kimura, Fumihiko
    Kato, Koji
    Uchida, Naoyuki
    Ikegame, Kazuhiro
    Onizuka, Makoto
    Matsuoka, Ken-ichi
    Doki, Noriko
    Kawakita, Toshiro
    Onishi, Yasushi
    Yano, Shingo
    Fukuda, Takahiro
    Takanashi, Minoko
    Kanda, Yoshinobu
    Atsuta, Yoshiko
    Ogata, Masao
    [J]. BONE MARROW TRANSPLANTATION, 2020, 55 (09) : 1784 - 1795
  • [6] National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
    Jagasia, Madan H.
    Greinix, Hildegard T.
    Arora, Mukta
    Williams, Kirsten M.
    Wolff, Daniel
    Cowen, Edward W.
    Palmer, Jeanne
    Weisdorf, Daniel
    Treister, Nathaniel S.
    Cheng, Guang-Shing
    Kerr, Holly
    Stratton, Pamela
    Duarte, Rafael F.
    McDonald, George B.
    Inamoto, Yoshihiro
    Vigorito, Afonso
    Arai, Sally
    Datiles, Manuel B.
    Jacobsohn, David
    Heller, Theo
    Kitko, Carrie L.
    Mitchell, Sandra A.
    Martin, Paul J.
    Shulman, Howard
    Wu, Roy S.
    Cutler, Corey S.
    Vogelsang, Georgia B.
    Lee, Stephanie J.
    Pavletic, Steven Z.
    Flowers, Mary E. D.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (03) : 389 - 401
  • [7] Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients
    Ke, P.
    Bao, X-B
    Hu, X-H
    Zhuang, J.
    Wu, X-J
    Liu, Y-J
    He, X-F
    Wu, D-P
    Xue, S-L
    Ma, X.
    [J]. BONE MARROW TRANSPLANTATION, 2018, 53 (02) : 162 - 168
  • [8] Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance
    Kim, Young-June
    Broxmeyer, Hal E.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 79 (02) : 112 - 126
  • [9] Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study
    Lin, Ren
    Wang, Yu
    Huang, Fen
    Fan, Zhiping
    Zhang, Shen
    Yang, Ting
    Xu, Yajing
    Xu, Na
    Xu, Li
    Ye, Jieyu
    Sun, Jing
    Huang, Xiaojun
    Liu, Qifa
    [J]. BMC MEDICINE, 2019, 17 (01):
  • [10] Combination of haploidentical haematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: a report of 146 cases
    Liu, Limin
    Zhang, Yanming
    Jiao, Wenjing
    Zhou, Huifen
    Wang, Qingyuan
    Qiu, Huiying
    Tang, Xiaowen
    Han, Yue
    Fu, Chengcheng
    Jin, Zhengming
    Chen, Suning
    Sun, Aining
    Miao, Miao
    Wu, Depei
    [J]. BONE MARROW TRANSPLANTATION, 2020, 55 (10) : 2017 - 2025